38 Jermyn Street
13 articles about Abingworth LLP
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
London-based venture capital fund Abingworth closed on a new Clinical Co-Development Fund now at $582 million. The fund's original target was just at $350 million.
Oversubscribed transatlantic fund to invest in US, UK and European life science companies developing innovative therapeutics with potential to significantly improve human health
Proceeds to advance development of Tildacerfont in Congenital Adrenal Hyperplasia and other indications
He succeeds James Abell who is retiring after 21 years with the firm.
Abingworth today announced that Brian Gallagher, PhD, will join Abingworth as a Partner based in the company’s Boston office.
7/9/2018Abingworth Bioventures closed out its latest investment fund aimed at supporting life science companies with $315 million. The latest fund, ABV VII, will be used to support investments in Europe and the United States.
Life Sciences Investor, Abingworth Management Ltd., Nearing Final Close Of $374 Million+ Bioventure Fund